| Authors: |
Wang S; Center for Asian Health and Viral Hepatitis Programs, Cooperman Barnabas Medical Center, New Jersey Medical School, Livingston, NJ, USA., Harrington M; Treatment Action Group, New York, NY, USA., Graham CS; Division of Infectious Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Downs LO; Nuffield Department of Medicine, University of Oxford, Oxford, UK; KEMRI Wellcome Trust Research Programme, Kilifi, Kenya., Kagwanja N; KEMRI Wellcome Trust Research Programme, Kilifi, Kenya., Etyang AO; KEMRI Wellcome Trust Research Programme, Kilifi, Kenya., Iwuji C; Department of Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, UK; Africa Health Research Institute, KwaZulu Natal, South Africa., Ndung'u T; Africa Health Research Institute, KwaZulu Natal, South Africa; Division of Infection and Immunity, University College London, London, UK; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Mass General Brigham, MIT and Harvard, Cambridge, MA, USA., Cowie BC; Department of Infectious Diseases, The University of Melbourne, Melbourne, VIC, Australia., Kabagambe K; The National Organisation for People Living with Hepatitis B, Kampala, Uganda., Matthews PC; Division of Infection and Immunity, University College London, London, UK; The Francis Crick Institute, London, UK; Department of Infectious Diseases, University College London Hospital, London NW1 2BU, UK. Electronic address: philippa.matthews@crick.ac.uk. |
